CBER Reorganization Poses “Significant” Staff Retention Issues – Zoon
This article was originally published in The Gray Sheet
Executive Summary
The reorganization of FDA's Center for Biologics Evaluation & Research poses a significant problem for employee retention, Director Kathryn Zoon told the FDA Science Board Oct. 25
You may also be interested in...
CBER staff changes
Sixty-three of 213 CBER Office of Therapeutic Research & Review FTEs are reassigned to CBER's Office of Cellular Tissue & Gene Therapies, while the remaining FTEs will be transferred to the drug center, FDA reports. The Jan. 8 agency memo details phase two of a three-part plan to shift review of biologic therapeutic products to the Center for Drug Evaluation & Research. The restructuring was announced last fall (1"The Gray Sheet" Nov. 22, 2002, p.11)...
CBER staff changes
Sixty-three of 213 CBER Office of Therapeutic Research & Review FTEs are reassigned to CBER's Office of Cellular Tissue & Gene Therapies, while the remaining FTEs will be transferred to the drug center, FDA reports. The Jan. 8 agency memo details phase two of a three-part plan to shift review of biologic therapeutic products to the Center for Drug Evaluation & Research. The restructuring was announced last fall (1"The Gray Sheet" Nov. 22, 2002, p.11)...
CBER Deputy Director Goodman To Assume Biologics Directorship In January
Incoming Center for Biologics Evaluation & Research Director Jesse Goodman, MD, brings a working relationship with blood test manufacturers from his experience as CBER deputy director